NEW YORK, Nov. 11, 2009 (GLOBE NEWSWIRE) -- Prana Biotechnology (Nasdaq:PRAN) (ASX:PBT) today announced that Dr. Rudy Tanzi, Scientific Advisory Board will present at the 2009 Windhover's Therapeutic Area Partnerships Conference being held November 18 at 3:30PM at the Westin Copley Place Hotel in Boston.
Prana's lead Alzheimer's disease compound, PBT2, has been chosen by Windhover Information and independent expert Harry Tracy, as one of the top 10 most interesting neuroscience projects in development available for strategic partnering.
About Windhover
Windhover Information Inc. (www.windhover.com), an Elsevier company, has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, the Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into Alzheimer's Disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.
For further information please visit the Company's web site at www.pranabio.com.